Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.1
3.0
Journals
Antibodies
Special Issues
Antibody Gene Libraries
share announcement

Antibody Gene Libraries

A special issue of Antibodies (ISSN 2073-4468).

Deadline for manuscript submissions: closed (28 February 2015) | Viewed by 18045

Special Issue Editor

Dr. Ahuva Nissim

E-Mail Website
Guest Editor
Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Chaterhouse Square, London EC1M 6BQ, UK
Interests: arthropathies; type 1 diabetes; autoimmune condition; targeted immunotherapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Since the first publication by Kohler and Milstein on the production of mouse monoclonal antibodies (mAbs) by hybridoma technology, mAbs have had a profound impact on medicine and have become a major part of treatments for various ailments, including transplantation, oncology, autoimmune, cardiovascular, and infectious diseases. While murine, chimeric, and humanized mAbs have been approved for treatment, future opportunities rely on the development of fully human antibodies for clinical applications. Remarkable progress in this direction has been made following the development of antibody gene libraries, namely the display technologies that enable the engineering of antibodies with modified properties (e.g., molecular size, affinity, specificity, and valency).

In this Special Issue of Antibodies, gene libraries will highlight advances in the display technologies that can be sources of fully human antibodies engineered for optimal clinical performance. The issue will review the various antibody displayed formats (e.g., phage, yeast, bacteria or cells). Alternative libraries that are not based on an antibody backubone will also be described. Examples of clinical applications will be reviewed.

Dr. Ahuva Nissim
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


Keywords

  • phage display
  • yeast display
  • cell display
  • bacterial display
  • scFv, domain
  • alternative backbone libraries

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

2169 KiB  
Article
Purpose-Oriented Antibody Libraries Incorporating Tailored CDR3 Sequences
by Pauline Bonvin, Sophie Venet, Marie Kosco-Vilbois and Nicolas Fischer
Antibodies 2015, 4(2), 103-122; https://doi.org/10.3390/antib4020103 - 20 May 2015
Cited by 5 | Viewed by 9330
Abstract
The development of in vitro antibody selection technologies has allowed overcoming some limitations inherent to the hybridoma technology. In most cases, large repertoires of antibody genes have been assembled to create highly diversified libraries allowing the isolation of antibodies recognizing virtually any antigen. [...] Read more.
The development of in vitro antibody selection technologies has allowed overcoming some limitations inherent to the hybridoma technology. In most cases, large repertoires of antibody genes have been assembled to create highly diversified libraries allowing the isolation of antibodies recognizing virtually any antigen. However, these universal libraries might not allow the isolation of antibodies with specific structural properties or particular amino acid contents that are rarely found in natural repertoires. Purpose-oriented libraries specially designed to incorporate desired characteristics have been successfully used. However, the workload required for library construction has limited the attractiveness of this approach compared to the use of large universal libraries. We have developed an approach to capture synthetic or natural diversity into the complementarity determining regions 3 (CDR3) of human antibody repertoires using Type IIS restriction enzymes. In this way, we generated several libraries either biased in amino acid content or towards long CDRH3 loops. The latter were successfully used to identify antibodies inhibiting the enzymatic activity of horseradish peroxidase, whereas libraries enriched in histidines allowed for the isolation of antibodies binding to human Fc in a pH-dependent manner. These libraries indicate that tailored diversification of CDR3 is sufficient to generate purpose-oriented libraries and isolate antibodies with uncommon properties. Full article
(This article belongs to the Special Issue Antibody Gene Libraries)
►▼ Show Figures

Graphical abstract

1203 KiB  
Article
A Monoclonal Antibody to Human DLK1 Reveals Differential Expression in Cancer and Absence in Healthy Tissues
by Emil Bujak, Danilo Ritz and Dario Neri
Antibodies 2015, 4(2), 71-87; https://doi.org/10.3390/antib4020071 - 16 Apr 2015
Cited by 4 | Viewed by 8224
Abstract
There is considerable interest in the characterization of novel tumor-associated antigens that lend themselves to antibody-mediated pharmacodelivery strategies. Delta-like 1 homolog protein (DLK1), which exists both as transmembrane protein and in soluble form, shows a restricted pattern of expression in healthy organs, while [...] Read more.
There is considerable interest in the characterization of novel tumor-associated antigens that lend themselves to antibody-mediated pharmacodelivery strategies. Delta-like 1 homolog protein (DLK1), which exists both as transmembrane protein and in soluble form, shows a restricted pattern of expression in healthy organs, while being overexpressed in some tumors. We have generated a human antibody specific to DLK1 using phage display technology. This reagent was used for a comprehensive characterization of DLK1 expression in freshly frozen sections of normal human adult tissues and of xenografted human tumors. DLK1 was virtually undetectable in most organs, except for placenta which was weakly positive. By contrast, DLK1 exhibited a moderate-to-strong expression in 8/9 tumor types tested. Our analysis shed light on previous conflicting reports on DLK1 expression in health and disease. The study suggests that DLK1 may be considered as a target for antibody-mediated pharmacodelivery strategies, in view of the protein’s limited expression in normal tissues and its abundance in the interstitium of neoplastic lesions. Full article
(This article belongs to the Special Issue Antibody Gene Libraries)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop